Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (DBS Neurostimulator Implantable B35200)
Medtronic, Inc. · Decision date Oct 29, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-10-29 for PMA supplement P960009/S547, a 30-Day Notice submitted by Medtronic, Inc. under the supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The supplement concerns the Activa Deep Brain Stimulation Therapy System, specifically the Percept PC BrainSense DBS Neurostimulator Implantable B35200, a device in the implanted electrical stimulator category for parkinsonian tremor (product code MHY, Neurology). The action covers the listed manufacturing process changes rather than a new approval of the whole system.
The recorded statement lists six changes: enhanced operator verification of the FactoryWorks processing step and recorded battery pre-weight; pre-weight and post-weight out-of-control action plans added to Process Operation Descriptions; software and Human Machine Interface updates that automatically reject batteries with fill weights above the established final-fill reasonable limit; dedicated white work-in-progress trays for electrolyte-filled batteries; an isopropyl alcohol wipe to remove residual electrolyte before subsequent processing; and removal of Ball Press and Button Press certification prerequisites from the ram-change procedure for Medium Rate Line 2 operators, with supervisors and engineers retaining certification responsibility. No supporting documents were included, so the basis for OK30 and any clinical implications remain unknown.
FDA approval order statement
1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P960009/S547
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- MHY
- Decision code
- OK30
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian tremor.
- Applicant
- Medtronic, Inc.
- Product code
- MHY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960009 · Original PMA
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEM
P960009/S546 · Related supplement
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEM
P960009/S547 received
Application receipt date recorded by FDA.
P960009/S542 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense
P960009/S547 · FDA decision
30-Day Notice
P960009/S548 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense
P960009/S545 · Related supplement
Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (B32000)
Timeline entries are records held by MedtechLedger for P960009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Jul 31, 1997 | FDA | |
MEDTRONIC ACTIVA TREMOR CONTROL SYSTEMP960009/S546 | Medtronic, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Nov 8, 2026 | FDA |
Explore the linked device profile
Other records with product code MHY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
Deep Brain Stimulation (DBS) EPGP140009/S141 | ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
Infinity DBS IPGP140009/S139 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P960009/S547
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
